Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide.
This study investigated the chemical and physical stability of afamelanotide (melanotan-1), a synthetic 13-amino acid peptidomimetic of α-melanocyte stimulating hormone (α-MSH) approved as an orphan drug for erythropoietic protoporphyria. Researchers subjected the compound to a range of stress conditions — acidic, basic, neutral, oxidative, UV light exposure, and elevated temperature (60°C) — following International Council for Harmonisation (ICH) guidelines Q1A(R2) and Q5C. Using gradient reversed-phase HPLC coupled with ultra-high-performance liquid chromatography–high resolution tandem mass spectrometry (UHPLC-HRMS/MS), the team identified and structurally characterized 14 distinct degradation products. Collision-induced dissociation fragmentation patterns enabled detailed elucidation of each product's structure. Key degradation pathways identified included truncation, methylation, deacetylation, and oxidation. The analytical method was validated per ICH Q2(R1) guidelines. This work is purely analytical and pharmaceutical in nature — it does not involve human subjects, animals, or cell-based experiments. Its primary value lies in establishing a comprehensive stability profile of afamelanotide to inform rational drug formulation design. No clinical outcomes, efficacy, or safety data in biological systems were assessed.